ZA200204188B - Substituted oxazolidinones and their use in the field of blood coagulaton. - Google Patents
Substituted oxazolidinones and their use in the field of blood coagulaton. Download PDFInfo
- Publication number
- ZA200204188B ZA200204188B ZA200204188A ZA200204188A ZA200204188B ZA 200204188 B ZA200204188 B ZA 200204188B ZA 200204188 A ZA200204188 A ZA 200204188A ZA 200204188 A ZA200204188 A ZA 200204188A ZA 200204188 B ZA200204188 B ZA 200204188B
- Authority
- ZA
- South Africa
- Prior art keywords
- radical
- alkyl
- group
- general formula
- optionally
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title claims description 6
- 239000008280 blood Substances 0.000 title claims description 4
- 210000004369 blood Anatomy 0.000 title claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 47
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 239000001257 hydrogen Substances 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 31
- 229910052717 sulfur Inorganic materials 0.000 claims description 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 150000001204 N-oxides Chemical class 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- 150000004677 hydrates Chemical class 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- -1 amino, aminomethyl Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000001544 thienyl group Chemical group 0.000 claims description 11
- 229930192474 thiophene Natural products 0.000 claims description 11
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 230000009424 thromboembolic effect Effects 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 4
- 108010074860 Factor Xa Proteins 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 206010038563 Reocclusion Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 229930188620 butyrolactone Natural products 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 4
- 239000012442 inert solvent Substances 0.000 claims 4
- 150000001735 carboxylic acids Chemical class 0.000 claims 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical class 0.000 claims 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000001174 sulfone group Chemical group 0.000 claims 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 59
- 230000023555 blood coagulation Effects 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- UHKAJLSKXBADFT-UHFFFAOYSA-N 1,3-indandione Chemical class C1=CC=C2C(=O)CC(=O)C2=C1 UHKAJLSKXBADFT-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19962924A DE19962924A1 (de) | 1999-12-24 | 1999-12-24 | Substituierte Oxazolidinone und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200204188B true ZA200204188B (en) | 2003-05-27 |
Family
ID=7934434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200204188A ZA200204188B (en) | 1999-12-24 | 2002-05-27 | Substituted oxazolidinones and their use in the field of blood coagulaton. |
Country Status (50)
Families Citing this family (248)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| WO2003106413A2 (en) * | 2001-10-18 | 2003-12-24 | Michigan State University | Process for the preparation of oxazolidinones and method of use thereof |
| DE10152460A1 (de) * | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
| US7022705B2 (en) | 2001-10-25 | 2006-04-04 | Astrazeneca Ab | Isoxazoline derivatives useful as antimicrobials |
| CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| US7012088B2 (en) | 2003-02-24 | 2006-03-14 | Pharmacia & Upjohn Company | Indolone oxazolidinones and derivatives thereof |
| DE10322469A1 (de) * | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| DE10336716A1 (de) * | 2003-08-11 | 2005-03-10 | Merck Patent Gmbh | Verfahren zur Herstellung von N-Aryl-morpholinonen |
| DE10342570A1 (de) * | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| DE102004002044A1 (de) * | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
| US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
| EP1571154A1 (en) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Beta-aminoacid-derivatives as factor Xa inhibitors |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| KR20070012552A (ko) * | 2004-05-13 | 2007-01-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 치환된 티오펜카복스아미드, 이의 제조방법 및약제로서의 이의 용도 |
| EP1748997A1 (de) * | 2004-05-13 | 2007-02-07 | Boehringer Ingelheim International Gmbh | Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| MXPA06013960A (es) * | 2004-06-18 | 2007-03-15 | Millennium Pharm Inc | Inhibidores del factor xa. |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| ATE429423T1 (de) * | 2004-07-20 | 2009-05-15 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| PE20060619A1 (es) * | 2004-07-29 | 2006-07-11 | Ferrer Int | Derivados de oxazolidinona como antibacterianos |
| DE102004047840A1 (de) * | 2004-09-29 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004050283A1 (de) * | 2004-10-15 | 2006-04-27 | Lanxess Deutschland Gmbh | 4-Aminophenyl-morpholinon-Derivate und deren Herstellung |
| US7662837B2 (en) | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| US7645755B2 (en) | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| ATE499370T1 (de) | 2005-01-19 | 2011-03-15 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen |
| EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| DE102005018690A1 (de) * | 2005-04-22 | 2006-10-26 | Bayer Healthcare Ag | Imino-oxazolidine und ihre Verwendung |
| US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| ES2352796T3 (es) | 2005-06-27 | 2011-02-23 | Bristol-Myers Squibb Company | Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas. |
| US7728008B2 (en) | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE602006020871D1 (de) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
| US7714002B2 (en) | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| PE20070171A1 (es) * | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
| WO2007007588A1 (ja) * | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| US20070032473A1 (en) * | 2005-07-19 | 2007-02-08 | Kai Gerlach | Substituted amides and their use as medicaments |
| AR057976A1 (es) * | 2005-08-29 | 2008-01-09 | Boehringer Ingelheim Int | Biarilos sustituidos y su uso como medicamentos. |
| DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
| DE102005047564A1 (de) | 2005-10-04 | 2007-05-31 | Bayer Healthcare Ag | Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid |
| DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| SG166126A1 (en) * | 2005-10-04 | 2010-11-29 | Bayer Schering Pharma Ag | Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
| DE102005048824A1 (de) * | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
| KR101443651B1 (ko) | 2005-10-18 | 2014-09-23 | 얀센 파마슈티카 엔.브이. | Ｆｌｔ-3 키나제의 억제 방법 |
| US7962847B2 (en) * | 2005-10-20 | 2011-06-14 | International Business Machines Corporation | Method for providing dynamic process step annotations |
| DE102005052174A1 (de) * | 2005-11-02 | 2007-06-06 | Bayer Healthcare Ag | Phenylen-bis-oxazolidin-Derivate und ihre Verwendung |
| JP2007154330A (ja) * | 2005-12-01 | 2007-06-21 | Nippon Paper Industries Co Ltd | 印刷用塗工紙 |
| WO2007079186A2 (en) * | 2005-12-30 | 2007-07-12 | Merck & Co., Inc. | 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors |
| DE102006007146A1 (de) | 2006-02-16 | 2007-08-23 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
| CN101460495B (zh) | 2006-03-31 | 2013-08-14 | 财团法人乙卯研究所 | 具有杂环的化合物 |
| JP5595727B2 (ja) | 2006-04-20 | 2014-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃ−ｋｉｔキナーゼ阻害法 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| AU2007240437B2 (en) | 2006-04-20 | 2012-12-06 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
| JP5331680B2 (ja) | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼの阻害剤 |
| AU2007240439B2 (en) | 2006-04-20 | 2012-10-11 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| EP2016072B1 (en) | 2006-05-05 | 2014-07-16 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| DE102006025319A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Aktiengesellschaft | Substituierte Heterozyklen und ihre Verwendung |
| DE102006025314A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Arylsubstituierte Heterozyklen und ihre Verwendung |
| DE102006034916A1 (de) * | 2006-07-28 | 2008-01-31 | Bayer Healthcare Ag | Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten |
| DE102006039589A1 (de) * | 2006-08-24 | 2008-03-06 | Bayer Healthcare Ag | Aminoacyl-Prodrugs II |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| CN101605779B (zh) | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
| PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| EP2114930A2 (en) * | 2007-01-05 | 2009-11-11 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| EP2141154A4 (en) | 2007-03-30 | 2011-06-01 | Inst Med Molecular Design Inc | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11-HYDROXYSTEOID DEHYDROGENASE TYPE I |
| DE102007018662A1 (de) | 2007-04-20 | 2008-10-23 | Bayer Healthcare Ag | Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie |
| AU2008241091B2 (en) | 2007-04-23 | 2013-05-09 | Sanofi-Aventis | Quinoline-carboxamide derivatives as P2Y12 antagonists |
| WO2008140220A1 (en) * | 2007-05-09 | 2008-11-20 | Legochem Bioscience Ltd. | Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof |
| KR101009594B1 (ko) | 2007-05-09 | 2011-01-20 | 주식회사 레고켐 바이오사이언스 | Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물 |
| DE102007028318A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Oxazolidinone zur Behandlung und Prophylaxe von Sepsis |
| DE102007028407A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028406A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028320A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007037373A1 (de) | 2007-08-06 | 2009-02-19 | Schebo Biotech Ag | Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie |
| WO2009018807A1 (de) * | 2007-08-06 | 2009-02-12 | Schebo Biotech Ag | Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie |
| US20090076264A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched rivaroxaban |
| EP2233484A3 (en) | 2007-10-02 | 2012-04-04 | Research Foundation Itsuu Laboratory | Oxazolidinone derivatives having a 7-membered heterocyclic ring |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| EP2220079A2 (en) * | 2007-11-15 | 2010-08-25 | Boehringer Ingelheim International GmbH | Substituted amides, manufacturing and use thereof as medicaments |
| RU2494740C2 (ru) * | 2007-12-11 | 2013-10-10 | Байер Интеллектуэль Проперти Гмбх | Оксазолидиноны для лечения и/или профилактики расстройств сердечной деятельности |
| WO2009080226A2 (en) | 2007-12-26 | 2009-07-02 | Sanofis-Aventis | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| CA2758424C (en) | 2008-04-21 | 2018-03-06 | Signum Biosciences, Inc. | Tryptamine derivatives as pp2a methylation modulators |
| DE102008028071A1 (de) | 2008-06-12 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure |
| EP2138178A1 (en) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma |
| KR100898361B1 (ko) * | 2008-07-03 | 2009-05-20 | 주식회사 레고켐 바이오사이언스 | Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물 |
| EP2140866A1 (en) | 2008-07-04 | 2010-01-06 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract |
| WO2010003641A1 (en) | 2008-07-08 | 2010-01-14 | Ratiopharm Gmbh | Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| KR101023174B1 (ko) * | 2008-09-24 | 2011-03-18 | 주식회사 레고켐 바이오사이언스 | 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
| US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
| EP4242206A1 (en) * | 2009-01-30 | 2023-09-13 | Novartis AG | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| US7816355B1 (en) * | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
| EP2266541A1 (en) | 2009-06-18 | 2010-12-29 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
| LT2442799T (lt) | 2009-06-18 | 2016-12-27 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kieta farmacinė kompozicija, apimanti rivaroksabaną |
| KR101037052B1 (ko) | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체 |
| KR101037051B1 (ko) | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | (ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법 |
| PL2459555T3 (pl) | 2009-07-31 | 2022-03-28 | Krka, D.D., Novo Mesto | Sposoby krystalizacji rywaroksabanu |
| EP2485715A1 (en) | 2009-10-06 | 2012-08-15 | Ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
| EP2308472A1 (en) | 2009-10-06 | 2011-04-13 | ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
| WO2011061760A1 (en) * | 2009-11-18 | 2011-05-26 | Cadila Healthcare Limited | Novel antithrombotic agents |
| CN102762550B (zh) | 2009-12-17 | 2015-04-01 | 米伦纽姆医药公司 | Xa因子抑制剂的盐和结晶形式 |
| US8742120B2 (en) * | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| EP2521723A1 (en) * | 2010-01-04 | 2012-11-14 | Enantia, S.L. | Process for the preparation of rivaroxaban and intermediates thereof |
| EP2354128A1 (en) * | 2010-02-10 | 2011-08-10 | Sandoz Ag | Method for the preparation of rivaroxaban |
| JP5841547B2 (ja) | 2010-02-11 | 2016-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としてのマクロ環 |
| EA015918B1 (ru) | 2010-03-03 | 2011-12-30 | Дмитрий Геннадьевич ТОВБИН | УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| DE102010028362A1 (de) | 2010-04-29 | 2011-11-03 | Bayer Schering Pharma Aktiengesellschaft | Herstellverfahren |
| KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| EP2388260A1 (de) | 2010-05-21 | 2011-11-23 | Archimica GmbH | Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors |
| CN102311400A (zh) * | 2010-06-29 | 2012-01-11 | 翔真生物科技股份有限公司 | 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法 |
| EP2404920A1 (en) | 2010-07-06 | 2012-01-11 | Sandoz AG | Crystalline form of Rivaroxaban dihydrate |
| US20130253187A1 (en) * | 2010-09-14 | 2013-09-26 | Medichem, S.A. | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative |
| CZ2010714A3 (cs) | 2010-09-30 | 2012-04-11 | Farmak, A. S. | Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote |
| CA2815063C (en) | 2010-10-18 | 2016-11-22 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
| CN102464658B (zh) * | 2010-11-03 | 2014-04-16 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
| DE102010063127A1 (de) | 2010-12-15 | 2012-06-21 | Bayer Schering Pharma Aktiengesellschaft | Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| US20140050743A1 (en) | 2011-01-19 | 2014-02-20 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
| CN102199150A (zh) * | 2011-04-01 | 2011-09-28 | 中国药科大学 | 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途 |
| WO2012140061A1 (en) | 2011-04-11 | 2012-10-18 | Sandoz Ag | Method for the preparation of substituted oxazolidinones |
| MD4557C1 (ro) * | 2011-05-06 | 2018-10-31 | Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu |
| WO2012156983A1 (en) * | 2011-05-16 | 2012-11-22 | Symed Labs Limited | Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
| ES2395304B1 (es) | 2011-05-20 | 2014-01-16 | Interquim, S.A. | Procedimiento de obtención de una tiofen-2-carboxamida. |
| CN102796092B (zh) * | 2011-05-24 | 2015-04-08 | 北大方正集团有限公司 | 噁唑烷酮衍生物及其制备方法和应用 |
| CN102796091A (zh) * | 2011-05-24 | 2012-11-28 | 北大方正集团有限公司 | 取代的噁唑烷酮化合物及其制备方法和应用 |
| CN102320988B (zh) * | 2011-06-03 | 2014-04-09 | 中国科学院上海有机化学研究所 | 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途 |
| CN102827154B (zh) | 2011-06-14 | 2015-04-22 | 上海科胜药物研发有限公司 | 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| EP2753619A2 (en) | 2011-09-08 | 2014-07-16 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
| EP2573084A1 (en) | 2011-09-22 | 2013-03-27 | Enantia, S.L. | Novel crystalline forms of rivaroxaban and processes for their preparation |
| WO2013046211A1 (en) * | 2011-09-27 | 2013-04-04 | Symed Labs Limited | Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof |
| WO2013053739A1 (en) | 2011-10-10 | 2013-04-18 | Laboratorios Lesvi, S. L. | Process for preparing factor xa inhibitors |
| HU230734B1 (hu) | 2011-10-10 | 2017-12-28 | EGIS Gyógyszergyár Nyrt | Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok |
| EP2766373B1 (en) * | 2011-10-11 | 2016-08-17 | Council of Scientific & Industrial Research | Sila analogs of oxazolidinone derivatives and synthesis thereof |
| IN2014CN02805A (it) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| TWI586651B (zh) | 2011-10-14 | 2017-06-11 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物 |
| CN102408420B (zh) * | 2011-10-19 | 2014-10-22 | 汕头经济特区鮀滨制药厂 | 一种利伐沙班及其中间体的制备方法以及中间体化合物 |
| EP2812329A2 (en) | 2012-02-06 | 2014-12-17 | Megafine Pharma (P) Ltd. | A process for preparation of rivaroxaban and intermediates thereof |
| CZ2012111A3 (cs) | 2012-02-16 | 2013-08-28 | Zentiva, K.S. | Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu |
| CZ2012114A3 (cs) | 2012-02-17 | 2013-02-20 | Zentiva, K.S. | Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu |
| CN103288814B (zh) | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | 一种利伐沙班中间体的制备方法 |
| WO2013151719A2 (en) * | 2012-04-05 | 2013-10-10 | Scifluor Life Sciences, Llc | Fluorinated oxazolidinone derivatives |
| US9562040B2 (en) | 2012-04-06 | 2017-02-07 | Indiana University Research And Technology Corporation | Processes for preparing Rivaroxaban |
| WO2013156936A1 (en) | 2012-04-16 | 2013-10-24 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban and intermediates thereof |
| CN104487436B (zh) | 2012-05-02 | 2017-05-24 | 信谊实验室有限公司 | 使用中间产物制备利伐沙班的改良方法 |
| US20150133657A1 (en) * | 2012-05-24 | 2015-05-14 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
| CN102746287B (zh) * | 2012-06-21 | 2014-05-28 | 成都苑东药业有限公司 | 一种恶唑烷酮化合物及其制备方法 |
| UY34856A (es) | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
| CN102757424B (zh) * | 2012-07-09 | 2014-10-15 | 云南大学 | 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法 |
| CN102746288B (zh) * | 2012-07-24 | 2015-04-08 | 常州制药厂有限公司 | 一种抗凝血药及其关键中间体的制备方法 |
| HUE031582T2 (en) | 2012-08-03 | 2017-07-28 | Bristol Myers Squibb Co | Dihydropyridone as xia factor inhibitors |
| PL2880026T3 (pl) | 2012-08-03 | 2017-08-31 | Bristol-Myers Squibb Company | Dihydropirydon P1 jako inhibitory czynnika XIA |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| AU2013299922B2 (en) | 2012-08-07 | 2018-06-21 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
| CN103626749A (zh) * | 2012-08-21 | 2014-03-12 | 苏州泽璟生物制药有限公司 | 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途 |
| IN2015DN02600A (it) | 2012-09-26 | 2015-09-18 | Ranbaxy Lab Ltd | |
| CN103864773B (zh) * | 2012-12-13 | 2017-03-15 | 北京藏卫信康医药研发有限公司 | 利伐沙班及其中间体的制备方法 |
| EP3309158B1 (en) | 2012-12-21 | 2022-03-16 | Krka, tovarna zdravil, d.d. | Crystalline form k of rivaroxaban and process for its preparation |
| AU2013368847B2 (en) * | 2012-12-26 | 2017-03-16 | Wanbury Ltd. | Aldehyde derivative of substitute oxazolidinones |
| PT2895176T (pt) | 2012-12-26 | 2017-01-27 | Wanbury Ltd | Intermediário de rivaroxabano e a sua preparação |
| WO2014155259A2 (en) * | 2013-03-25 | 2014-10-02 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of rivaroxaban |
| US9738655B2 (en) | 2013-03-25 | 2017-08-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors |
| CN104098556B (zh) * | 2013-04-09 | 2019-01-08 | 浙江九洲药物科技有限公司 | 一种利伐沙班的合成工艺 |
| CN104163819A (zh) * | 2013-05-17 | 2014-11-26 | 天津药物研究院 | 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途 |
| CN103242307B (zh) * | 2013-05-17 | 2015-08-12 | 天津药物研究院有限公司 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
| WO2014195230A1 (de) | 2013-06-03 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituierte benzoxazole |
| CA2914040A1 (en) * | 2013-06-03 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases |
| UY35592A (es) | 2013-06-03 | 2014-12-31 | Bayer Pharma AG | Benzoxazoles sustituidos |
| WO2015011617A1 (en) | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
| IN2013MU02699A (it) * | 2013-08-19 | 2015-06-19 | Amneal Pharmaceuticals Llc | |
| WO2015104605A1 (en) | 2014-01-08 | 2015-07-16 | Wockhardt Limited | A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof |
| IN2014CH00290A (it) | 2014-01-23 | 2015-08-14 | Symed Labs Ltd | |
| NO2760821T3 (it) | 2014-01-31 | 2018-03-10 | ||
| CN110845498B (zh) | 2014-01-31 | 2023-02-17 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
| WO2015124995A1 (en) | 2014-02-19 | 2015-08-27 | Aurobindo Pharma Ltd | Solid dosage forms of rivaroxaban |
| WO2015155307A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
| CN104974149B (zh) * | 2014-04-14 | 2018-05-01 | 北大方正集团有限公司 | 一种利伐沙班的制备方法 |
| CN105085371B (zh) * | 2014-04-22 | 2017-06-16 | 北大方正集团有限公司 | (s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法 |
| KR101499867B1 (ko) * | 2014-04-22 | 2015-03-06 | 에스케이케미칼주식회사 | 활성 성분 (i) 함유 조성물 및 이의 제조 방법 |
| CN105085370B (zh) * | 2014-04-22 | 2017-04-12 | 北大方正集团有限公司 | (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法 |
| WO2015169957A1 (en) | 2014-05-09 | 2015-11-12 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists |
| CN104031036A (zh) * | 2014-05-16 | 2014-09-10 | 南通常佑药业科技有限公司 | 一种利伐沙班的制备方法 |
| JP2017516845A (ja) | 2014-05-22 | 2017-06-22 | ノース チャイナ ファーマシューティカル カンパニー リミテッド | 血液凝固因子Ｘａ阻害剤としてのヒドラジド化合物 |
| CN103980221B (zh) * | 2014-05-26 | 2016-03-23 | 山东康美乐医药科技有限公司 | 4-（硝基苯基）-3-吗啉酮的制备方法及利用其制备利伐沙班的方法 |
| DE102014108210A1 (de) * | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| WO2015198259A1 (en) | 2014-06-26 | 2015-12-30 | Erregierre S.P.A. | Process for the synthesis of rivaroxaban and intermediate for the production thereof |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| US10214520B2 (en) | 2014-07-15 | 2019-02-26 | Gruenenthal Gmbh | Substituted azaspiro(4.5)decane derivatives |
| CN104086539A (zh) * | 2014-07-17 | 2014-10-08 | 天津炜捷制药有限公司 | 一种利伐沙班的制备方法 |
| WO2016030669A1 (en) | 2014-08-25 | 2016-03-03 | Cipla Limited | Process for the preparation of rivaroxaban |
| NO2721243T3 (it) | 2014-10-01 | 2018-10-20 | ||
| CN104356124A (zh) * | 2014-10-30 | 2015-02-18 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其组合物和用途 |
| CN104402876A (zh) * | 2014-11-25 | 2015-03-11 | 沈阳药科大学 | 噁唑烷酮类化合物及其应用 |
| CN104478869B (zh) * | 2014-12-05 | 2017-04-12 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN104478866B (zh) * | 2014-12-05 | 2017-07-07 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN104447729A (zh) * | 2014-12-05 | 2015-03-25 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN104447728B (zh) * | 2014-12-05 | 2017-01-04 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN104496978A (zh) * | 2014-12-09 | 2015-04-08 | 广东东阳光药业有限公司 | 取代噁唑烷酮类化合物及其使用方法和用途 |
| CN104530029B (zh) * | 2014-12-09 | 2017-04-12 | 广东东阳光药业有限公司 | 作为Xa因子抑制剂的杂环化合物及其使用方法和用途 |
| CN104497008B (zh) * | 2014-12-09 | 2016-11-16 | 广东东阳光药业有限公司 | 取代噁唑烷酮类化合物及其使用方法和用途 |
| CN104530031A (zh) * | 2014-12-10 | 2015-04-22 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN104530030A (zh) * | 2014-12-10 | 2015-04-22 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN104530080B (zh) * | 2014-12-10 | 2017-01-11 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| CN105777734A (zh) * | 2014-12-22 | 2016-07-20 | 常州方楠医药技术有限公司 | 一种利伐沙班中间体的合成方法 |
| CN104557900A (zh) * | 2014-12-23 | 2015-04-29 | 中国药科大学 | 噁唑烷酮类化合物及其制备方法与医药用途 |
| CN105820161A (zh) * | 2015-01-08 | 2016-08-03 | 常州方楠医药技术有限公司 | 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法 |
| TR201501970A2 (en) | 2015-02-19 | 2016-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of dronedarone. |
| WO2016150785A1 (en) * | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
| WO2016150937A1 (en) | 2015-03-25 | 2016-09-29 | Lonza Ltd | Method for preparation of thiophenecarbonyl chlorides |
| CN104926807B (zh) * | 2015-06-04 | 2017-10-31 | 沈阳药科大学 | 一种利伐沙班相关物质“二胺”及其合成方法 |
| JP6742348B2 (ja) | 2015-06-19 | 2020-08-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としてのジアミド大員環 |
| ES2871111T3 (es) | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático |
| EP3331872B1 (en) | 2015-08-05 | 2019-09-25 | Bristol-Myers Squibb Company | Novel substituted glycine derived fxia inhibitors |
| EP3325476B1 (en) | 2015-11-04 | 2018-09-26 | Lonza Ltd | Method for preparation of thiophene-2-carbonyl chlorides |
| HUE056739T2 (hu) | 2016-02-23 | 2022-03-28 | Morgandane Scient Llc | Páciensek kezelése rivaroxaban és verapamil együttes beadásával |
| US10752641B2 (en) | 2016-03-02 | 2020-08-25 | Bristol-Myers Squibb Company | Diamide macrocycles having factor XIa inhibiting activity |
| EP3263096A1 (en) | 2016-06-28 | 2018-01-03 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical capsule composition of rivaroxaban |
| CN106588905A (zh) * | 2016-12-13 | 2017-04-26 | 重庆英斯凯化工有限公司 | 一种利伐沙班中间体的制备方法 |
| ES2923932T3 (es) * | 2017-01-04 | 2022-10-03 | Unichem Lab Ltd | Un procedimiento mejorado para la preparación de rivaroxabán que implica un intermedio novedoso |
| CN107586291B (zh) * | 2017-11-03 | 2019-08-20 | 梯尔希（南京）药物研发有限公司 | 一种利伐沙班代谢物5的合成方法 |
| CN107857739A (zh) * | 2017-11-14 | 2018-03-30 | 安徽华胜医药科技有限公司 | 一种氘代利伐沙班关键中间体及其制备方法 |
| CN107857761A (zh) * | 2017-11-14 | 2018-03-30 | 安徽华胜医药科技有限公司 | 一种氘代利伐沙班及其制备方法 |
| CN108164519A (zh) * | 2017-12-28 | 2018-06-15 | 江苏悦兴医药技术有限公司 | 利伐沙班工艺杂质的合成方法 |
| EP4257136A3 (en) | 2017-12-31 | 2023-11-29 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof |
| HU231119B1 (hu) | 2018-01-12 | 2020-11-30 | Richter Gedeon Nyrt. | Eljárás 4-(4-aminofenil)morfolin-3-on előállítására |
| US10828310B2 (en) | 2018-02-02 | 2020-11-10 | Bayer Pharma Aktiengesellschaft | Reducing the risk of cardiovascular events |
| GB201807014D0 (en) | 2018-04-30 | 2018-06-13 | Univ Leeds Innovations Ltd | Factor xlla inhibitors |
| CN108546265A (zh) * | 2018-06-22 | 2018-09-18 | 苏州中联化学制药有限公司 | 一种利伐沙班中间体的合成方法 |
| US10722486B2 (en) | 2018-08-13 | 2020-07-28 | Morgandane Scientific, LLC | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil |
| EP3796915A4 (en) | 2018-11-16 | 2022-01-26 | Santa Farma Ilaç Sanayi A.S. | ORAL FORMULATIONS CONTAINING RIVAROXABAN |
| CN110054621A (zh) * | 2019-03-12 | 2019-07-26 | 浙江天宇药业股份有限公司 | 一种利伐沙班中间体的制备方法 |
| CN110615756A (zh) * | 2019-06-28 | 2019-12-27 | 南京红杉生物科技有限公司 | 1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用 |
| US11608320B2 (en) | 2020-02-02 | 2023-03-21 | Kuwait University | Oxazolidinone hydroxamic acid derivatives |
| CN111253383A (zh) * | 2020-03-27 | 2020-06-09 | 南京国星生物技术研究院有限公司 | 一种利伐沙班的合成方法 |
| CN112159402B (zh) * | 2020-10-28 | 2022-04-05 | 南京法恩化学有限公司 | 一种利伐沙班的制备方法 |
| GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| GB202107722D0 (en) | 2021-05-28 | 2021-07-14 | Lunac Therapeutics Ltd | Factor XIIA Inhibitors |
| CN115260117B (zh) * | 2022-08-09 | 2024-05-28 | 江苏法安德医药科技有限公司 | 一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1035546B (de) | 1955-02-16 | 1958-07-31 | Max Ruf | Torbegrenzung fuer Ballspiele |
| US2811555A (en) * | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
| US3279880A (en) * | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
| LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
| US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
| US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| HU190072B (en) * | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| ES8506659A1 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
| ATE95176T1 (de) | 1987-10-21 | 1993-10-15 | Du Pont Merck Pharma | Aminomethyl-oxo-oxazolidinyl-ethenylbenzenderivate, nuetzlich als antibakterielles mittel. |
| DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US5254577A (en) * | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| CA2119556C (en) | 1991-11-01 | 2004-07-06 | Michael Robert Barbachyn | Substituted aryl- and heteroaryl-phenyloxazolidinones |
| SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
| US5349045A (en) * | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
| ES2134870T3 (es) * | 1993-05-01 | 1999-10-16 | Merck Patent Gmbh | Antagonistas del receptor de adhesion. |
| US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| DE4332384A1 (de) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
| EP0807112B1 (en) * | 1995-02-03 | 2001-09-05 | PHARMACIA & UPJOHN COMPANY | Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials |
| HRP960159A2 (en) * | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
| DE19524765A1 (de) * | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| RU2175324C2 (ru) | 1995-09-01 | 2001-10-27 | Фармация Энд Апджон Компани | Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами |
| JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン ｎ−オキシド |
| DE19601264A1 (de) * | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
| DE19604223A1 (de) * | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
| HRP970049A2 (en) * | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
| GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
| DK0930076T3 (da) | 1996-07-15 | 2005-01-31 | Sankyo Co | Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| ATE293609T1 (de) | 1997-05-30 | 2005-05-15 | Upjohn Co | Antibakteriell wirksam oxazolidinone mit einer thiocarbonylfunktionalität |
| WO1999002525A1 (en) | 1997-07-11 | 1999-01-21 | Pharmacia & Upjohn Company | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents |
| DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
| GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| HUP0100470A3 (en) | 1997-11-12 | 2002-08-28 | Upjohn Co | Oxazolidinone derivatives and pharmaceutical compositions containing them |
| US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
| DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
| DE19802239A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Neue mit Bicyclen substituierte Oxazolidinone |
| EP1049682A1 (en) | 1998-01-23 | 2000-11-08 | Versicor, Inc. | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| ATE346050T1 (de) | 1998-01-27 | 2006-12-15 | Aventis Pharma Inc | Substituierte oxoazaheterocyclyl faktor xa hemmer |
| DE19805117A1 (de) | 1998-02-09 | 1999-08-12 | Bayer Ag | Neue Oxazolidinone mit azolhaltigen Tricyclen |
| US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
| TR200003384T2 (tr) | 1998-05-18 | 2001-03-21 | Pharmacia & Upjohn Company | Arginin türevleri kullanılarak oksazolidinon antibakteriyel maddelerin etkisinin arttırılması |
| DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
| PE20010851A1 (es) | 1999-12-14 | 2001-08-17 | Upjohn Co | Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina |
| PL356478A1 (en) | 1999-12-21 | 2004-06-28 | Pharmacia & Upjohn Company | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| WO2001047949A1 (fr) | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Cristaux de derives d'aspartame |
| DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
| DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10152460A1 (de) | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
| DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| DE102004002044A1 (de) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| CA2597263C (en) | 2005-02-14 | 2017-01-17 | Epitopix, Llc | Polypeptides from staphylococcus aureus and methods of use |
| DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
| SG166126A1 (en) | 2005-10-04 | 2010-11-29 | Bayer Schering Pharma Ag | Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
| DE102005047558A1 (de) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| DE102005048824A1 (de) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
| KR101378695B1 (ko) * | 2007-04-18 | 2014-03-31 | 삼성전자주식회사 | 통신 시스템에서의 훈련 시퀀스 코드 생성 방법 및 장치 |
-
1999
- 1999-12-24 DE DE19962924A patent/DE19962924A1/de not_active Withdrawn
-
2000
- 2000-11-29 HN HN2000000267A patent/HN2000000267A/es unknown
- 2000-12-11 KR KR1020077008192A patent/KR20070044075A/ko not_active Application Discontinuation
- 2000-12-11 UA UA2002076161A patent/UA73339C2/uk unknown
- 2000-12-11 CN CNB008189668A patent/CN1262551C/zh not_active Expired - Lifetime
- 2000-12-11 WO PCT/EP2000/012492 patent/WO2001047919A1/de active Application Filing
- 2000-12-11 MX MXPA02006241A patent/MXPA02006241A/es active IP Right Grant
- 2000-12-11 DK DK00993610T patent/DK1261606T3/da active
- 2000-12-11 AU AU28414/01A patent/AU775126C/en not_active Expired
- 2000-12-11 PL PL355665A patent/PL200413B1/pl unknown
- 2000-12-11 EP EP04027037.3A patent/EP1526132B1/de not_active Expired - Lifetime
- 2000-12-11 BR BRPI0017050-0A patent/BR0017050B1/pt active IP Right Grant
- 2000-12-11 SI SI200030679T patent/SI1261606T1/xx unknown
- 2000-12-11 JP JP2001549389A patent/JP4143297B2/ja not_active Expired - Lifetime
- 2000-12-11 PT PT00993610T patent/PT1261606E/pt unknown
- 2000-12-11 ES ES04027037.3T patent/ES2457021T3/es not_active Expired - Lifetime
- 2000-12-11 SI SI200031079T patent/SI1526132T1/sl unknown
- 2000-12-11 DE DE50009607T patent/DE50009607D1/de not_active Expired - Lifetime
- 2000-12-11 SK SK908-2002A patent/SK287272B6/sk not_active IP Right Cessation
- 2000-12-11 EP EP00993610A patent/EP1261606B1/de not_active Expired - Lifetime
- 2000-12-11 AT AT00993610T patent/ATE289605T1/de active
- 2000-12-11 KR KR1020077020537A patent/KR20070094672A/ko not_active Application Discontinuation
- 2000-12-11 DK DK04027037.3T patent/DK1526132T3/da active
- 2000-12-11 NZ NZ519730A patent/NZ519730A/en not_active IP Right Cessation
- 2000-12-11 TR TR2004/01314T patent/TR200401314T2/xx unknown
- 2000-12-11 HU HU0203902A patent/HU226522B1/hu active Protection Beyond IP Right Term
- 2000-12-11 PT PT40270373T patent/PT1526132E/pt unknown
- 2000-12-11 TR TR2002/01636T patent/TR200201636T2/xx unknown
- 2000-12-11 EE EEP200200341A patent/EE05169B1/xx active Protection Beyond IP Right Term
- 2000-12-11 RU RU2002120456/04A patent/RU2297415C2/ru active Protection Beyond IP Right Term
- 2000-12-11 SG SG200403830-3A patent/SG130939A1/en unknown
- 2000-12-11 NZ NZ537058A patent/NZ537058A/en not_active IP Right Cessation
- 2000-12-11 ES ES00993610T patent/ES2237497T3/es not_active Expired - Lifetime
- 2000-12-11 CN CNB2005101271139A patent/CN100549008C/zh not_active Expired - Lifetime
- 2000-12-11 PL PL382243A patent/PL201121B1/pl unknown
- 2000-12-11 CN CN2006100819193A patent/CN1900074B/zh not_active Expired - Lifetime
- 2000-12-11 CA CA002396561A patent/CA2396561C/en not_active Expired - Lifetime
- 2000-12-11 IL IL14989600A patent/IL149896A0/xx active Protection Beyond IP Right Term
- 2000-12-11 CZ CZ20022202A patent/CZ301432B6/cs not_active IP Right Cessation
- 2000-12-11 US US10/181,051 patent/US7157456B2/en not_active Expired - Lifetime
- 2000-12-11 KR KR1020027008172A patent/KR100804932B1/ko active IP Right Review Request
- 2000-12-11 DE DE122009000014C patent/DE122009000014I1/de active Pending
- 2000-12-18 AR ARP000106733A patent/AR032436A1/es active IP Right Grant
- 2000-12-19 GT GT200000216A patent/GT200000216A/es unknown
- 2000-12-20 TW TW089127307A patent/TWI226330B/zh active
- 2000-12-20 DO DO2000000114A patent/DOP2000000114A/es unknown
- 2000-12-20 TW TW083120747A patent/TWI277615B/zh not_active IP Right Cessation
- 2000-12-21 SV SV2000000245A patent/SV2002000245A/es active IP Right Grant
- 2000-12-22 CO CO00097415A patent/CO5251440A1/es active IP Right Grant
- 2000-12-22 MY MYPI20006170A patent/MY140488A/en unknown
- 2000-12-22 PE PE2000001388A patent/PE20010963A1/es not_active IP Right Cessation
-
2002
- 2002-05-27 ZA ZA200204188A patent/ZA200204188B/en unknown
- 2002-06-07 CU CU20020114A patent/CU23208A3/es unknown
- 2002-06-14 BG BG106825A patent/BG65683B1/bg unknown
- 2002-06-21 NO NO20023043A patent/NO323699B1/no not_active IP Right Cessation
- 2002-06-21 MA MA26708A patent/MA25646A1/fr unknown
- 2002-07-23 HR HR20020617A patent/HRP20020617B1/xx not_active IP Right Cessation
-
2004
- 2004-01-20 HK HK04100440A patent/HK1057556A1/xx not_active IP Right Cessation
- 2004-01-20 HK HK06112529.9A patent/HK1092140A1/xx not_active IP Right Cessation
- 2004-10-13 AU AU2004218729A patent/AU2004218729A1/en not_active Withdrawn
- 2004-10-13 CU CU20040221A patent/CU23423B7/es unknown
- 2004-12-10 JP JP2004358908A patent/JP5190173B2/ja not_active Expired - Lifetime
-
2006
- 2006-07-18 HR HRP20060251AA patent/HRP20060251B1/hr not_active IP Right Cessation
- 2006-07-27 US US11/460,529 patent/US7592339B2/en not_active Expired - Fee Related
-
2007
- 2007-02-20 NO NO20070981A patent/NO20070981L/no not_active Application Discontinuation
- 2007-07-17 HK HK07107638.6A patent/HK1103235A1/xx not_active IP Right Cessation
- 2007-10-31 US US11/932,082 patent/US7576111B2/en not_active Expired - Fee Related
-
2008
- 2008-01-11 DO DO2008000001A patent/DOP2008000001A/es unknown
- 2008-02-07 US US12/027,553 patent/US7585860B2/en not_active Expired - Fee Related
- 2008-11-19 LU LU91497C patent/LU91497I2/xx unknown
- 2008-11-25 NL NL300370C patent/NL300370I2/nl unknown
- 2008-12-02 CY CY200800019C patent/CY2008019I2/el unknown
- 2008-12-04 LT LTPA2008018C patent/LTC1261606I2/lt unknown
- 2008-12-10 BE BE2008C046C patent/BE2008C046I2/fr unknown
- 2008-12-11 FR FR08C0051C patent/FR08C0051I2/fr active Active
-
2009
- 2009-01-08 NO NO2009001C patent/NO2009001I1/no not_active IP Right Cessation
- 2009-06-30 US US12/494,879 patent/US8129378B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 IL IL205242A patent/IL205242A/en unknown
-
2012
- 2012-01-27 US US13/360,107 patent/US8530505B2/en not_active Expired - Fee Related
- 2012-06-22 UY UY0001034152A patent/UY34152A/es not_active Application Discontinuation
-
2013
- 2013-08-07 US US13/961,264 patent/US8822458B2/en not_active Expired - Fee Related
-
2014
- 2014-05-29 CY CY20141100383T patent/CY1115117T1/el unknown
- 2014-07-21 US US14/336,379 patent/US20150166568A1/en not_active Abandoned
-
2021
- 2021-02-25 NO NO2021009C patent/NO2021009I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200204188B (en) | Substituted oxazolidinones and their use in the field of blood coagulaton. | |
| US6534535B1 (en) | Inhibitors of factor Xa | |
| JP2009511513A5 (it) | ||
| JP4390099B2 (ja) | 置換された２−オキソ−３−フェニル−５−カルボニルアミノメチル−１，３−オキサゾリンならびにその抗凝固剤および抗血栓剤としての使用 | |
| US6403633B2 (en) | Heteroaryl amidines, methylamidines and guanidines, and use thereof as protease inhibitors | |
| US6653340B1 (en) | Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation | |
| EP1054886B1 (en) | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors | |
| JP2003500386A (ja) | Ｘａ因子阻害剤 | |
| KR20090107499A (ko) | 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법 | |
| CA2362375A1 (en) | Alkenyl and alkynyl compounds as inhibitors of factor xa | |
| JP2002502852A5 (it) | ||
| AU2007297013B2 (en) | Isoserine derivatives for use as coagulation factor IXa inhibitors | |
| JP2003500390A (ja) | Ｘａ因子阻害剤 | |
| AU2004279412B2 (en) | Thioether-substituted benzamides as inhibitors of Factor Xa | |
| ZA200106849B (en) | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors. | |
| JP2008521844A (ja) | 環状イミノカルバメート類およびそれらの使用 | |
| US20040077690A1 (en) | Quaternary amidino based inhibitors of factor xa | |
| CN104529933A (zh) | 取代邻苯甲酰磺酰亚胺类组蛋白去乙酰化酶抑制剂及制备方法和应用 | |
| WO2002026718A2 (en) | Bicyclic pyrimidin-4-one based inhibitors of factor xa | |
| WO2003048155A1 (en) | Thrombin inhibitors | |
| Kalay | Synthesis and characterization of novel hybrid sulfonamide molecules with benzothiazole scaffold | |
| CA2379375A1 (en) | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | |
| CN101180296B (zh) | 用作Xa因子抑制剂的杂芳基-甲酸（氨磺酰基烷基）酰胺衍生物 | |
| JP2003503391A (ja) | ６−カルボキシフェニルジヒドロピリダジノン誘導体及びその使用 | |
| KR100227730B1 (ko) | 트롬빈 억제제로서 유용한 신규한 벤즈아미딘계 하이덴토인 유도체 |